Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3% – What’s Next?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) fell 4.3% during trading on Friday . The company traded as low as $74.60 and last traded at $74.4630. 49,622 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,433,523 shares. The stock had previously closed at $77.81.

Analyst Ratings Changes

KYMR has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday, October 8th. Oppenheimer boosted their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. UBS Group upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Thursday, December 4th. Bank of America upped their price objective on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $116.30.

Kymera Therapeutics Stock Down 6.9%

The firm’s 50-day simple moving average is $71.31 and its 200-day simple moving average is $55.77. The firm has a market capitalization of $5.21 billion, a PE ratio of -20.22 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The company had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 229,809 shares of Kymera Therapeutics stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57. Following the transaction, the director directly owned 686,477 shares of the company’s stock, valued at $62,970,535.21. The trade was a 25.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the completion of the transaction, the insider owned 109,992 shares in the company, valued at $6,755,708.64. The trade was a 35.13% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 518,585 shares of company stock valued at $43,749,999. 16.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE increased its holdings in shares of Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after acquiring an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Kymera Therapeutics by 9.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after purchasing an additional 248 shares during the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after buying an additional 540 shares during the last quarter. Finally, Comerica Bank raised its holdings in Kymera Therapeutics by 3.6% in the first quarter. Comerica Bank now owns 21,374 shares of the company’s stock worth $585,000 after buying an additional 743 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.